Translating the Role of Neurotransmitter Systems into Clinical Outcomes in Schizophrenia and Bipolar Disorder
neuroscienceCME VOICE
Premiere Date: Monday, June 11, 2007Live Audioconference Series (10 sessions): June - July, 2007
This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Certified Case Managers (CCMC)
Credit Expiration Date:
Thursday, July 10, 2008
 | Charles B. Nemeroff, MD, PhD Professor and Chairman Department of Psychiatry and Behavioral Sciences Leonard M. Miller School of Medicine University of Miami Miami, FL |
 | Peter F. Buckley, MD Professor and Chairman Department of Psychiatry and Health Behavior Associate Dean for Leadership Development Medical College of Georgia Augusta, GA |
There is a distinct overlap between schizophrenia and bipolar disorder, especially in the area of
neurobiology. The same neurotransmitter systems are responsible for the core behaviors that
are common to both conditions: energy and interest (norepinephrine); impulse control (5-HT);
and drive/psychosis (dopamine). Schizophrenia and BPD also share many of the same medical
comorbidities - obesity, diabetes mellitus, and cardiovascular disease - while shared psychiatric
comorbidities include anxiety, eating disorders, substance abuse, and personality disorders.
Atypical antipsychotics have an affinity for the serotonergic neurotransmitter system in addition to
their effects on the dopamine D2 receptor that may influence clinical outcomes. It may also explain
their clinical profile of lower EPS and improvement in cognition, which is not observed with the
conventional agents. However, weight gain, increased blood lipids/cholesterol, insulin resistance/
type 2 diabetes, and hyperprolactinemia are emerging as significant treatment-associated concerns
with selected agents. In this live and interactive, evidence-based neuroscienceCME VOICE activity,
the experts will explore the link between neurotransmitter systems and clinical outcomes to
maximize treatment strategies in patients with schizophrenia and bipolar disorder.
To recognize the relationship between neurotransmitter systems and clinical outcomes in patients with schizophrenia and bipolar disorder.
At the end of this CE activity, participants should be able to:
- Recognize the relationship between neurotransmitter systems and clinical outcomes in patients with schizophrenia and bipolar disorder.
- Compare and contrast the pharmacologic properties of antipsychotics in an evidence-based model to identify the most appropriate therapy for each patient.
- Design and implement a treatment strategy that incorporates non-pharmacologic and pharmacologic strategies to improve outcomes in patients with schizophrenia and bipolar disorder.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.
CME Outfitters, LLC, gratefully acknowledges an educational grant from Wyeth Pharmaceuticals and Solvay Pharmaceuticals in support of this CE activity.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the
Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
CME Outfitters, LLC, designates this educational
activity for a maximum of 1.0 AMA PRA Category
1 Credit(s)™. Physicians should only claim credit
commensurate with the extent of their participation
in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.
CNE Credit (Nurses):
CME Outfitters, LLC, is an
approved provider of continuing nursing education
by the New York State Nurses Association, an
accredited approver by the American Nurses
Credentialing Center’s Commission on Accreditation.
It has been assigned code 6WASUP-PRV-064.
1.0 contact hours will be awarded upon successful
completion.
Note to Nurse Practitioners: The content of this CNE
activity pertains to Pharmacology.
CEP Credit (Psychologists):
CME Outfitters is
approved by the American Psychological Association
to sponsor continuing education for psychologists.
CME Outfitters maintains responsibility for this
program and its content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was
approved by the National Association of Social
Workers (provider #886407722) for 1 continuing
education contact hour.
CCMC Credit (Certified Case Managers):
This
program has been approved for 1 hour by the
Commission for Case Manager Certification (CCMC).
CPE Credit (Pharmacists):
CME Outfitters, LLC, is
accredited by the Accreditation Council
for Pharmacy Education as a provider of
continuing pharmacy education.
1.0 contact hours (0.1 CEUs)
Universal Program Number:
376-999-07-005-L01 (live presentation)
376-999-07-005-H01 (recorded programs)
To receive credit, participants must review all activity
materials in their entirety, score 70% or above on
a post-test, and fully complete and return both
the credit request form and activity evaluation. A
certificate or statement of credit will be mailed within
4-6 weeks to all who successfully complete these
requirements.
Disclosure Declaration
All faculty participating in CME Outfitters continuing education activities are required to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME's Standards for Commercial Support, and other accrediting and regulatory bodies. Full disclosure of faculty relationships will be made on this website and within the activity course materials prior to the premiere date of this activity.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
VC-013-061107-14
